Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Targeted Therapy in EGFR Exon 20-Mutant Non-Small Cell Lung Cancer

April 25th 2018

Burden of EGFR Exon 20 Mutation in NSCLC

April 25th 2018

Durvalumab/Tremelimumab Misses Endpoint in Phase III NSCLC Study

April 24th 2018

Dual immune checkpoint blockade with durvalumab (Imfinzi) and tremelimumab did not induce a statistically significant improvement in overall survival in heavily pretreated patients with locally-advanced or metastatic NSCLC.

Dr. Yu on Treatments for EGFR-Mutant Lung Cancer

April 23rd 2018

Helena A. Yu, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatments for EGFR-mutant lung cancer.

Advances Continue With Targeted Agents in ALK+ NSCLC

April 21st 2018

Paul K. Paik, MD, discusses treatment advances and sequencing strategies for patients with ALK-positive NSCLC.

Expert Discusses Frontline Osimertinib Approval and Next Steps in EGFR+ NSCLC

April 20th 2018

Helena A. Yu, MD, discusses sequencing strategies in EGFR-mutant NSCLC, the impact of osimertinib in the frontline setting, and the questions surrounding dacomitinib’s intriguing data in this landscape.

Hellmann Expands on TMB Testing in Lung Cancer

April 20th 2018

Matthew D. Hellmann, MD, discusses the expansion of biomarkers across single-agent and combination therapies in patients with non–small cell lung cancer.

Dr. West on FDA Approval of Frontline Osimertinib in EGFR+ NSCLC

April 19th 2018

H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the FDA approval of osimertinib (Tagrisso) in the frontline setting for patients with EGFR-mutation

Future Treatment Strategies in Non-Small Cell Lung Cancer

April 19th 2018

Combination Strategies With VEGF-Targeted Therapy in NSCLC

April 19th 2018

NSCLC: Mechanisms of Resistance to Antiangiogenic Therapy

April 19th 2018

Clinical Implications of the REVEL Trial in NSCLC

April 19th 2018

NSCLC: Rapid Progression Data in the REVEL Trial

April 19th 2018

Treating NSCLC With Ramucirumab: The REVEL Trial

April 19th 2018

Patient Selection for Frontline Bevacizumab in NSCLC

April 19th 2018

Rationale Behind Antiangiogenic Therapy in NSCLC

April 19th 2018

FDA Approves Frontline Osimertinib for NSCLC

April 19th 2018

The FDA has approved osimertinib as a first-line treatment for patients with non–small cell lung cancer whose tumors harbor EGFR mutations (exon 19 deletions or exon 21 L858R substitution mutations).

FDA Grants Nivolumab Priority Review for SCLC

April 19th 2018

The FDA has granted a priority review to a supplemental biologics license application for nivolumab (Opdivo) for the treatment of patients with small cell lung cancer with disease progression following 2 or more lines of therapy.

Mutation Burden May Help Guide First-Line Immunotherapy in NSCLC

April 18th 2018

Tumor mutational burden in non–small cell lung cancer identified patients who were more likely to respond to first-line combination immunotherapy with nivolumab and ipilimumab, an updated analysis of CheckMate-586 clinical trial data showed.

Dr. Shaw Discusses Efficacy of Lorlatinib in ALK+ NSCLC

April 18th 2018

Alice T. Shaw, MD, PhD, associate professor of medicine, Harvard Medical School, attending physician, Thoracic Cancer Program, Massachusetts General Hospital, discusses the efficacy of lorlatinib in ALK-positive non–small cell lung cancer.